Tags

Type your tag names separated by a space and hit enter

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Mov Disord. 1999 Nov; 14(6):940-6.MD

Abstract

Single-photon emission computed tomography (SPECT) imaging with the dopamine transporter ligand, [123I] beta-CIT (2beta-carboxymethoxy-3beta-[4-iodophenyl] tropane), has been proposed as a means of measuring Parkinson's disease (PD) progression. To be useful in this role, however, [123I] beta-CIT imaging should not be influenced by the medications used to treat PD, including the dopamine agonist drugs such as pergolide. We assessed the effect of adjunctive pergolide administration on [123I] beta-CIT uptake in 12 patients with PD, who were being treated with levodopa, initiating pergolide therapy for motor fluctuations. Patients underwent [123I] beta-CIT imaging at baseline, subsequently while on pergolide therapy (6 weeks), and again 4 weeks after pergolide wash-out. Uptake in the striatum was averaged for the two sides and expressed as (striatum - occipital)/occipital, with similar calculations for putamen and caudate. Consistent with PD, the patients' mean striatal and putamen uptake ratios at baseline were significantly less (p <0.001) than the mean values from 26 normal control subjects of similar age. During pergolide treatment, the striatal and putamen [123I] beta-CIT uptake ratios were each statistically similar to baseline, although there was a slight trend toward an increased striatal value (8% higher on pergolide; p = 0.105). Caudate [123I] beta-CIT uptake was 11% higher on pergolide therapy (nominal p = 0.042, but not significant when adjusted for multiple comparisons: p = 0.126). After pergolide wash-out, the striatal, putamen, and caudate uptake ratios did not differ from baseline. Therefore, we found that pergolide therapy did not significantly affect [123I] beta-CIT SPECT imaging but we cannot exclude a small influence.

Authors+Show Affiliations

Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

10584667

Citation

Ahlskog, J E., et al. "The Effect of Dopamine Agonist Therapy On Dopamine Transporter Imaging in Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 14, no. 6, 1999, pp. 940-6.
Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord. 1999;14(6):940-6.
Ahlskog, J. E., Uitti, R. J., O'Connor, M. K., Maraganore, D. M., Matsumoto, J. Y., Stark, K. F., Turk, M. F., & Burnett, O. L. (1999). The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 14(6), 940-6.
Ahlskog JE, et al. The Effect of Dopamine Agonist Therapy On Dopamine Transporter Imaging in Parkinson's Disease. Mov Disord. 1999;14(6):940-6. PubMed PMID: 10584667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. AU - Ahlskog,J E, AU - Uitti,R J, AU - O'Connor,M K, AU - Maraganore,D M, AU - Matsumoto,J Y, AU - Stark,K F, AU - Turk,M F, AU - Burnett,O L, PY - 1999/12/10/pubmed PY - 1999/12/10/medline PY - 1999/12/10/entrez SP - 940 EP - 6 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 14 IS - 6 N2 - Single-photon emission computed tomography (SPECT) imaging with the dopamine transporter ligand, [123I] beta-CIT (2beta-carboxymethoxy-3beta-[4-iodophenyl] tropane), has been proposed as a means of measuring Parkinson's disease (PD) progression. To be useful in this role, however, [123I] beta-CIT imaging should not be influenced by the medications used to treat PD, including the dopamine agonist drugs such as pergolide. We assessed the effect of adjunctive pergolide administration on [123I] beta-CIT uptake in 12 patients with PD, who were being treated with levodopa, initiating pergolide therapy for motor fluctuations. Patients underwent [123I] beta-CIT imaging at baseline, subsequently while on pergolide therapy (6 weeks), and again 4 weeks after pergolide wash-out. Uptake in the striatum was averaged for the two sides and expressed as (striatum - occipital)/occipital, with similar calculations for putamen and caudate. Consistent with PD, the patients' mean striatal and putamen uptake ratios at baseline were significantly less (p <0.001) than the mean values from 26 normal control subjects of similar age. During pergolide treatment, the striatal and putamen [123I] beta-CIT uptake ratios were each statistically similar to baseline, although there was a slight trend toward an increased striatal value (8% higher on pergolide; p = 0.105). Caudate [123I] beta-CIT uptake was 11% higher on pergolide therapy (nominal p = 0.042, but not significant when adjusted for multiple comparisons: p = 0.126). After pergolide wash-out, the striatal, putamen, and caudate uptake ratios did not differ from baseline. Therefore, we found that pergolide therapy did not significantly affect [123I] beta-CIT SPECT imaging but we cannot exclude a small influence. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/10584667/The_effect_of_dopamine_agonist_therapy_on_dopamine_transporter_imaging_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/1531-8257(199911)14:6&lt;940::aid-mds1005&gt;3.0.co;2-y DB - PRIME DP - Unbound Medicine ER -